ABBOTT LABORATORIES (ABT) Stock Analysis

Analysis from 10-Q filed 2025-10-29. Data as of Q2 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 7.3%. FCF margin 16.8%. D/E 0.6x. Source: 10-Q filed 2025-10-29.

Metric	Value	Context
ROIC	7.3%	Below expectations
FCF Margin	16.8%	Strong cash generation
Debt/Equity	0.6x	Moderate leverage

ROIC 7.3% — Top 50% of sector peers. FCF margin 16.8% — Top 5%.

Explore ABBOTT LABORATORIES: Earnings History | Filings

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ABT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: ABBOTT LABORATORIES earns 7.3% ROIC, Top 50% in Healthcare

ROIC TTM 7.3%, sector median -5.0%, Top 50%. DuPont: NOPAT margin 11.4% × asset turnover 0.5x. Gross margin 56.6%. Operating margin 15.8%. Source: 10-Q filed 2025-10-29.

Metric	ABT	Rating	Context
Return on Invested Capital (ROIC)	7.3%	Warning	Above sector median of -5.0%
Return on Equity (ROE)	10.5%	Adequate	Moderate equity returns
Gross Margin	56.6%	Excellent	Strong pricing power
Operating Margin	15.8%	Good	Efficient operations

---

Cash Flow: ABBOTT LABORATORIES generates $7.8B FCF at 16.8% margin, positive NaN/8 quarters

FCF TTM $7.8B. FCF margin 16.8%, Top 5%. OCF/Net income 1.8x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-29.

Metric	ABT	Rating	Context
Free Cash Flow Margin	16.8%	Good	Excellent cash conversion
Free Cash Flow (TTM)	$7.8B	Good	Positive cash generation
OCF/Net Income	1.8x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: ABBOTT LABORATORIES at 0.6x leverage

Debt/Equity 0.6x. Total debt $32.6B, cash & investments $5.6B. Source: 10-Q filed 2025-10-29.

Metric	ABT	Rating	Context
Debt to Equity	0.6x	Good	Moderate leverage
Net Cash Position	$-27.0B	Warning	Net debt position

---

Valuation: ABBOTT LABORATORIES trades at 33.6x earnings

P/E 33.6x. EV/Sales 5.4x. FCF yield 4.3%. Dividend yield 2.4%. Source: 10-Q filed 2025-10-29.

Metric	ABT	Rating	Context
P/E Ratio	33.6x	Adequate	Premium valuation
EV/Sales	5.4x	Adequate	Growth premium priced in
FCF Yield	4.3%	Good	Lower cash yield
Dividend Yield	2.4%	Adequate	Growth focus over income

---

Capital Allocation: ABBOTT LABORATORIES returns 3.4% shareholder yield

Total shareholder yield 3.4% (div 2.4% + buyback 1.0%). Capital returned $6.2B TTM. Source: 10-Q filed 2025-10-29.

Metric	ABT	Rating	Context
Total Shareholder Yield	3.4%	Good	Dividend + buyback yield combined
Buyback Yield	1.0%	Adequate	Minimal buyback activity
Total Capital Returned (TTM)	$6.2B	Good	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	7.3%	Top 50%	-
Free Cash Flow Margin	16.8%	Top 5%	-
Gross Margin	56.6%	Bottom 50%	0.9x below
Operating Margin	15.8%	Top 25%	7.1x above
Return on Equity (ROE)	10.5%	Top 50%	-
P/E Ratio	33.6x	N/A	-

---

Financial Scorecard

Metric	ABT	Rating	Sector Context
Return on Invested Capital (ROIC)	7.3%	Warning	Top 50% of sector (median: -5.0%)
Free Cash Flow Margin	16.8%	Good	Top 5% of sector (median: 0.0%)
Gross Margin	56.6%	Excellent	Bottom 50% of sector (median: 64.6%)
Debt to Equity Ratio	63.8%	Good	Moderate leverage
P/E Ratio (Price-to-Earnings)	33.6x	Adequate	Growth premium
Free Cash Flow Yield	4.3%	Adequate	Moderate yield

---

Frequently Asked Questions

Q: What is ABBOTT LABORATORIES's Return on Invested Capital (ROIC)?

ABBOTT LABORATORIES (ABT) has a trailing twelve-month Return on Invested Capital (ROIC) of 7.3%. Sector median -5.0%. Source: 10-Q filed 2025-10-29.

Q: What is ABBOTT LABORATORIES's Free Cash Flow Margin?

ABBOTT LABORATORIES (ABT) has a free cash flow margin of 16.8%, generating $7.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-29.

Q: What is ABBOTT LABORATORIES's P/E ratio and how does it compare to peers?

ABBOTT LABORATORIES (ABT) trades at a P/E ratio of 33.6x, which is above the sector median of N/A. EV/Sales 5.4x. FCF yield 4.3%. Source: 10-Q filed 2025-10-29.

Q: Does ABBOTT LABORATORIES pay a dividend?

ABBOTT LABORATORIES (ABT) currently pays a dividend yield of 2.4%. Total shareholder yield (dividend + buybacks) 3.4%. Source: 10-Q filed 2025-10-29.

Q: How much debt does ABBOTT LABORATORIES have?

ABBOTT LABORATORIES (ABT) has a debt-to-equity ratio of 0.6x with total debt of $32.6 billion. Net debt $27.0 billion. Source: 10-Q filed 2025-10-29.

Q: What is ABBOTT LABORATORIES's revenue and earnings growth?

ABBOTT LABORATORIES (ABT) grew revenue by 8.1% year-over-year. EPS -61.1% YoY. Source: 10-Q filed 2025-10-29.

Q: Is ABBOTT LABORATORIES buying back stock?

ABBOTT LABORATORIES (ABT) repurchased $1.8 billion of stock over the trailing twelve months. This represents a buyback yield of 1.0%. Source: 10-Q filed 2025-10-29.

Q: How does ABBOTT LABORATORIES compare to competitors in Healthcare?

Compared to other companies in Healthcare, ABBOTT LABORATORIES (ABT) shows: ROIC 7.3%, sector median -5.0% (Top 50%). FCF margin 16.8%, sector median 0.0% (Top 5%). Gross margin 56.6%, 7.9pp below sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with ABBOTT LABORATORIES?

Quantitative warning flags for ABBOTT LABORATORIES (ABT): 1) ROIC declining -8.1% over 8 quarters. Source: 10-Q filed 2025-10-29.

---

Data Source: Data sourced from 10-Q filed 2025-10-29. TTM metrics as of Q2 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.